India Drug Pricing Regulator Slaps Novartis with "Over-Charging" Fine

Oct 14, 2014

Business Standard

India's National Pharmaceutical Pricing Authority (NPPA) has fined Novartis $49 million for overcharging for its best-selling painkiller, Voveran (also sold under the Voltaren trade name).

Voveran analgesic is based on diclofenac, a component that is under the Indian's government's direct price control. The new drug price control order, implemented in May 2013, capped the prices of 348 medicines at an average of the prices of all drugs with more than one per cent market share in their respective segments.

The pricing regulator's notice gave Novartis two weeks to explain why action should not be taken against it for overcharging.

Read the Business Standard article

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments